Loading patent…
AssigneeTopigen Pharmaceuticals Inc.
InventorsPaolo Renzi, Luc Paquet, Helene D'Anjou
Estimating the term…
The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
An oligonucleotide having a base sequence selected from the group consisting of (i) SEQ ID NOS. 1-92 and 113-126 and (ii) SEQ ID NOS. 1-92 and 113-126 containing a one base insertion, deletion or substitution.
(Canceled)
(Canceled)
(Canceled)
(Canceled)
(Canceled)
(Canceled)
(Canceled)
(Canceled)
A pharmaceutical composition comprising two oligonucleotides having SEQ ID NO. 54 and SEQ ID NO. 122 along with a pharmaceutically acceptable carrier.
An oligonucleotide that is at least 80% complementary to an mRNA of at least one of PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A1, PDE7A2, PDE7A3 and PDE7B, wherein at least one nucleotide of the oligonucleotide is a 2′-deoxy-2′-fluoroarabinonucleotide.
(canceled)
(Canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.